Why Gastroenterology Practices Lose the Most Revenue on Colonoscopy Billing

Your scheduler books it as a screening. Medicare pays it as a screening. Then, twenty minutes into the procedure, your physician finds a polyp and removes it and just like that, the claim that leaves your office is supposed to look completely different from the one that was scheduled.

Most of the time, it doesn’t and that gap between what happened in the room and what gets billed is one of the most consistent, most expensive revenue leaks in gastroenterology one that shows up on almost no dashboard, because it rarely triggers an outright denial. It just quietly pays less than it should.

If you run a gastroenterology practice, this isn’t a hypothetical. Industry analysis of GI revenue cycles puts the annual cost of screening-to-diagnostic conversion errors at roughly $140,000 to $220,000 for a typical practice not from fraud, not from bad intentions, but from a billing workflow that doesn’t update when the clinical reality does. For a practice performing several hundred colonoscopies a month, that number can be even higher.

The revenue problem, in plain terms

Colonoscopy billing runs on a fork in the road that most billing teams treat as a formality. It isn’t.

• A screening colonoscopy is billed under HCPCS codes G0105 (high-risk patient) or G0121 (average-risk patient) for Medicare, or CPT 45378 with modifier 33 for most commercial plans. It’s a preventive benefit for the patient owes nothing under the Affordable Care Act’s preventive services mandate.
• A diagnostic or therapeutic colonoscopy — one where a polyp is found and removed, tissue is biopsied, or a lesion is treated gets billed under the diagnostic CPT code range (45379–45398) that matches the actual procedure performed, such as 45385 for snare polypectomy, 45384 for hot biopsy forceps removal, or 45380 for biopsy alone.

When a screening converts mid-procedure, Medicare requires the PT modifier appended to the diagnostic CPT code, and commercial payers typically require modifier 33 in combination with the diagnostic code, though the exact requirement varies by plan. Get that wrong, and one of two things happens: the claim gets denied and rebilled (slow, costly, and often written off when staff are too busy to fight it), or it goes out clean but underpriced billed as a screening when it should have been diagnostic, so the practice collects the lower rate and nobody ever notices the difference on a claims report.

That second scenario is the expensive one, because it doesn’t trigger a denial. It just quietly costs you money, claim after claim, month after month, invisible to anyone who isn’t specifically looking for it.

Why this keeps happening even at well-run practices

The failure point usually isn’t the physician’s documentation or the coder’s knowledge of modifiers. It’s the handoff between them. A case gets scheduled as preventive. The op note reflects what actually happened polyp found, snare technique used, tissue sent to pathology. But the charge that reaches the billing team is still tagged with the original screening intent, because nothing in the workflow forces a re-check against the final outcome. If your practice relies on a general medical billing team rather than a GI-specialized one, this gap is common: broader billing operations may know the PT and 33 modifiers exist without knowing that a gastroenterology practice needs a hard stop between “op note finalized” and “claim submitted” specifically to catch this conversion every single time.

A General Scenario:

Consider a typical week at a mid-size gastroenterology practice: 40 to 60 colonoscopies scheduled as screenings. Industry data suggests that somewhere between a quarter and a third of screening colonoscopies convert to diagnostic once a polyp or lesion is found meaning 10 to 20 of those claims each week need the conversion modifier applied correctly. If even 3 or 4 of those get missed weekly, that’s over 150 underbilled or denied claims a year, each one representing the difference between a preventive-rate reimbursement and a diagnostic-rate reimbursement.

There’s a second layer to this that catches practices off guard: even when the conversion is coded correctly on the practice’s end, some commercial payers still process the converted colonoscopy as diagnostic for cost-sharing purposes meaning a patient who expected a $0 preventive visit gets a bill. Medicare has been phasing out the coinsurance on polyp removal during a screening colonoscopy since 2022 (it was 20%, dropping toward 0% by 2030 under a congressionally mandated phase-down passed as part of the Removing Barriers to Colorectal Cancer Screening Act), but commercial plans don’t follow that same schedule uniformly, and plan-level variation is common even within the same payer. When that surprise bill lands, it doesn’t just cost you a collections headache it costs you the patient relationship, and often a bad review that shows up right where your next new patient is searching for a GI practice.

The anesthesia claim gets missed too

Anesthesia billing for these cases has its own version of the same problem, and it’s one of the most commonly overlooked pieces of the conversion puzzle. When a screening colonoscopy converts to diagnostic, the anesthesia claim (typically CPT 00811 for lower intestinal endoscopy anesthesia, or 00812 for a straightforward screening) needs its own PT modifier applied separately from the endoscopy claim, on its own line, by whoever is billing the anesthesia component. Miss it, and the anesthesia coinsurance waiver doesn’t apply either, compounding the same error on a second line of the encounter. If your practice contracts with an independent anesthesia group for moderate sedation or MAC anesthesia during procedures, this hand-off becomes even more fragile, because two separate billing entities now both need to know the case converted and neither one automatically tells the other.

Moderate sedation reported under codes G0500 or 99153 has its own coinsurance waiver tied to modifier 33 when furnished alongside a screening colonoscopy. That waiver, too, depends on accurate, synchronized coding across every entity billing for the encounter.

What correcting this actually looks like

Fixing this isn’t about better intentions from your billing staff it’s about closing the specific gap where clinical outcome and billed code diverge. A gastroenterology-focused billing workflow builds in:

1. A mandatory cross-check between the final operative notes and the charge ticket before any screening-coded claim goes out the door, specifically looking for polypectomy, biopsy, or lesion-removal language that should trigger a PT or 33 modifiers. This should happen on 100% of screening-coded claims, not as a spot-check.
2. Payer-specific conversion rules kept current — because “how does this payer treat a converted screening” is not the same answer across Medicare, Medicaid MCOs, and every commercial plan your practice contracts with, and those rules shift, sometimes without much notice from the payer.
3. Pre-procedure patient cost estimates that account for the possibility of conversion, so a patient who ends up with a polypectomy isn’t blindsided by a bill they weren’t told to expect. A brief, standardized script at intake “if a polyp is found and removed, your cost-sharing may differ from a routine screening” prevents most of the downstream patient complaints.
4. A denial and underpayment audit specifically on colonoscopy claims — not just claims that got denied, but claims that got paid at the lower screening rate when the op note says otherwise. This is where most of the silent revenue loss hides, and it’s the audit most practices have never actually run.
5. Synchronized coding across every billing entity involved in the encounter — the endoscopy claim, the anesthesia claim, and the facility claim (whether ASC or hospital outpatient) all need to reflect the same conversion status.

What this is costing your practice right now

If you’ve never pulled a report cross-referencing screening-coded colonoscopy claims against operative notes showing polypectomy or biopsy, you likely have money sitting there that you don’t know about both underbilled claims already paid and denied claims that were written off instead of corrected and resubmitted. For a practice doing even a moderate colonoscopy volume, that gap adds up fast, and it compounds every month it goes unaddressed. Multiply a modest per-claim underpayment across hundreds of colonoscopies a year, and the $140,000–$220,000 industry figure stops looking like an outlier and starts looking like a conservative estimate for a lot of practices.

The ASC vs hospital outpatient factor

Where the procedure happens changes the math further. In an ambulatory surgery center, the facility bills separately under the ASC fee schedule, which typically reimburses at a lower rate than a hospital outpatient department billing under APC rules. Practices that own or partly own their ASC capture both the professional fee and the facility fee which means a missed conversion modifier costs them twice: once on the physician claim, once on the facility claim. The physician fee itself doesn’t change based on setting, but the total revenue at stake per case does, and practices with ASC ownership have meaningfully more to lose from a coding gap than those operating purely in a hospital outpatient setting.

Why AffinityCore is built for exactly this problem

Generic billing vendors treat gastroenterology like any other specialty same workflow, same generalist coders, same after-the-fact denial cleanup. AffinityCore doesn’t. Our gastroenterology billing team works exclusively with the conversion logic, payer-specific rules, and multi-entity claim synchronization described above, because we built our process around the way gastroenterology practices actually operate: high procedure volume, frequent screening-to-diagnostic conversions, and multiple billing entities touching a single encounter. That specialization is the difference between a billing partner who can explain what a PT modifier is, and one who has already built the systematic cross-check that catches it on every claim, every time which is exactly the kind of specialty-specific gap-closing that turns a generic vendor into a genuine revenue partner for your practice.

Frequently Asked Questions

Does Medicare still charge coinsurance if a polyp is removed during a screening colonoscopy?

Yes, but it’s shrinking. As of 2026, Medicare beneficiaries owe 15% coinsurance on the physician fee when a polyp is removed during a screening colonoscopy, a rate that’s phasing down to 0% by 2030 under federal law. Commercial payers set their own rules and don’t necessarily follow this same timeline.

What’s the difference between modifier PT and modifier 33?

Modifier PT is used on Medicare claims when a screening colonoscopy converts to diagnostic or therapeutic. Modifier 33 is used on commercial claims to indicate a preventive service. If a practice bills both a screening and a diagnostic component on the same encounter, 33 goes on the screening code and PT goes on the diagnostic code.

Can a claim be corrected after it’s already been paid at the wrong rate?

n most cases, yes payers generally allow a corrected claim or reprocessing request within a defined filing window (often 12 months, though this varies by payer). This is exactly why a periodic audit of paid screening claims against operative notes matters: underpayments caught within the window can often be recovered.

Does this issue affect ASC-owned practices differently than those using a hospital outpatient department?

Yes. In an ASC, the facility bills separately under the ASC fee schedule; in a hospital outpatient department, it’s billed under APC rules, which typically reimburse at a higher facility rate. Practices that own their ASC capture both professional and facility revenue, which makes getting the conversion coding right on both claims even more consequential.

How do I know if my practice has this problem?

Pull every claim from the last 6–12 months coded as a screening colonoscopy (G0105, G0121, or 45378 with modifier 33) and cross-reference against the operative notes for polypectomy, biopsy, or lesion-removal language. Any mismatch is a claim that was either underbilled or is at risk of a payer audit.